article

Delayed fingolimod-associated asystole

Patricio S Espinosa^a, Joseph R. Berger^b

^aNorth Oaks Neurology, Hammond, LA, USA
^bDepartment of Neurology, University of Kentucky, Lexington, KY, USA

Multiple Sclerosis Journal SAGE Publishing2011-06-07 77 citations7 references

Looking for the full paper…

Export

Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.

Abstract

Oral fingolimod (Gilenya) is a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes. Fingolimod reduces relapses and delays disability progression in patients with relapsing forms of multiple sclerosis (MS). We report a patient with MS who developed asystole and sustained bradycardia 21 hours after the first dose of fingolimod.

TL;DRA patient with MS who developed asystole and sustained bradycardia 21 hours after the first dose of fingolimod is reported. (Semantic Scholar)

Plain-language summary

AI illustration of the topic of “Delayed fingolimod-associated asystole”

Delayed fingolimod-associated asystole

Abstract

Plain-language summary

Discussion